CEO and Founding Director
Terasaki Institute for Biomedical Innovation
Ali Khademhosseini is the CEO and Founding Director of the Terasaki Institute for Biomedical Innovation. Previously, he was a Professor at UCLA and Harvard Medical School, with faculty roles at Harvard-MIT HST, Brigham and Women’s Hospital, and the Wyss Institute. He has authored over 800 publications, holds more than 50 patents, and has an H-index of 194. His research has led to groundbreaking advances in biomaterials and hydrogel technologies for healthcare. He earned his Ph.D. in bioengineering from MIT and his MASc and BASc in chemical engineering from the University of Toronto. He has founded three companies, including Obsidio Medical (acquired by Boston Scientific), Omeat, and BioRAE.